Cardiogenic shock can occur due to acute ischaemic or non-ischaemic cardiac events, or
from progression of long-standing underlying heart disease. When addressing the cause of …

The use of temporary mechanical circulatory support in cardiogenic shock has increased
dramatically despite a lack of randomized controlled trials or evidence guiding clinical …

Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is
increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial …

Over the past decade, the use of extracorporeal membrane oxygenation (ECMO) has
increased exponentially, from approximately 30–40 patients per year in the United States 20 …

Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly
used in patients with cardiogenic shock despite the lack of evidence from adequately …

Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) increases left
ventricular (LV) afterload, potentially provoking LV distention and impairing recovery. LV …

Cardiogenic shock (CS) remains the most common cause of mortality in patients with acute
myocardial infarction. The SHOCK trial (Should We Emergently Revascularize Occluded …

Cardiogenic shock accounts for~ 100,000 annual hospital admissions in the United States.
Despite improvements in medical management strategies, in-hospital mortality remains …

Venoarterial extracorporeal membrane oxygenation provides cardiorespiratory support to
patients in cardiogenic shock. This comes at the cost of increased left ventricle (LV) afterload …